Freenome agreed to merge with a SPAC to take the Bay Area liquid‑biopsy developer public with roughly $330 million in proceeds, including a $240 million PIPE commitment. The deal accelerates Freenome’s commercialization timeline as SimpleScreen, its colorectal‑cancer blood test, remains under FDA review with potential launch plans in 2026. If cleared, the test would compete directly with existing ctDNA players such as Guardant Health. The transaction provides Freenome with capital to support regulatory filing activities, scale manufacturing and execute on planned commercial partnerships. Investors backing the PIPE include Perceptive Advisors, RA Capital and other health‑focused funds, signaling continued institutional interest in multi‑cancer early detection despite ongoing debates about clinical utility and reimbursement.